
    
      This is a one-year, open-label, single arm, multicenter, phase IV study in patients with
      untreated active subfoveal Choroidal Neovascularization (CNV) secondary to wAMD The study
      consists of a screening period of up to 2 weeks and a treatment period with brolucizumab from
      Baseline (Day 1) up to Week 48.
    
  